Rallybio Showcases Promising Rare Disease Therapies at ASH Annual Meeting 2024

Rallybio Advances Research on Rare Disease Therapies at ASH Annual Meeting

Rallybio Corporation, a clinical-stage biotechnology firm specializing in treatments for rare diseases, makes a significant impact at the 66th American Society of Hematology (ASH) Annual Meeting by presenting promising preclinical data for its therapeutic candidates RLYB212 and RLYB332. The meeting, held from December 7 to 10, 2024, in San Diego, California, serves as a platform for Rallybio to showcase its innovative research, particularly in the field of maternal and fetal health, as well as iron overload diseases. CEO Dr. Stephen Uden emphasizes the importance of their ongoing Phase 2 trial for RLYB212, which aims to assess its safety and efficacy in preventing maternal alloimmunization and fetal/neonatal alloimmune thrombocytopenia (FNAIT) in at-risk pregnant women.

The research on RLYB212 reveals promising results, as preclinical studies demonstrate that the administration of the candidate at doses of 1.01 or 5.05 µg/kg to pregnant mice successfully prevents maternal alloimmunization. Notably, it results in normal platelet counts in the offspring, indicating its potential as a safe prophylactic treatment. The absence of thrombocytopenia in the pups further underlines the safety profile of RLYB212, making it a compelling candidate for future clinical applications aimed at protecting vulnerable populations during pregnancy. The detailed findings will be presented under the title “Prophylactic Administration of HPA-1a–Specific Antibody RLYB212 Safely Prevents Fetal/Neonatal Alloimmune Thrombocytopenia in Pregnant Mice,” which is set for display on December 7, 2024.

In addition to RLYB212, Rallybio introduces RLYB332, a long-acting anti-matriptase-2 antibody that exhibits significant pharmacodynamic effects, particularly in managing serum iron levels. The preclinical data showcase improvements in unsaturated iron binding capacity and transferrin saturation that surpass existing treatment options. This positions RLYB332 as a potential best-in-class therapy for iron overload diseases, reflecting Rallybio's commitment to addressing unmet medical needs. The positive tolerability profile observed in preclinical models further supports the therapeutic promise of RLYB332, contributing to Rallybio's mission of developing effective treatments for rare and severe conditions.

Overall, Rallybio's presentations at the ASH Annual Meeting highlight substantial advancements in the company’s pipeline, particularly regarding maternal health and iron overload disorders. By showcasing robust preclinical data, Rallybio not only positions itself as a leader in rare disease therapeutics but also underscores its dedication to improving health outcomes for patients facing significant medical challenges.